IND-enabling preclinical evaluation of a field-deployable synthetic

Ended Other Transaction Agreement Awarded Last action

Contract number
HR0011259E017
Awardee
Awarding agency
Obligated
$2,000,000

Award facts

Contract value 100% obligated
$2,000,000.00 Current and potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
Contracting staff
NAICS code
Not on record
Competition
Competed Broad Agency Announcement
Pricing
Other
Place of performance
Cleveland, OH 44106, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00002 · FY2024 - DARPA - sswhss_HT095712307799 - D2-2873/haima therapeutics, LLC $0
Funding Only Action P00001 · IND-enabling preclinical evaluation of a field-deploable synthetic platelet surrogate (synthoplate) for hemorrhage control $1,000,000
Original award IND-enabling preclinical evaluation of a field-deployable synthetic platelet surrogate (synthoplate) for hemorrhage control $1,000,000

About this award

The Defense Advanced Research Projects Agency awarded an Other Transaction Agreement to Haima Therapeutics LLC for $2,000,000 on September 19, 2025, to enable preclinical evaluation of a field-deployable synthetic platelet surrogate (Synthoplate) for hemorrhage control.

The OTA sits outside the Federal Acquisition Regulation and reflects DARPA's authority to pursue innovative prototype development. Haima Therapeutics is a woman-owned small business headquartered in Cleveland, Ohio. Work is performed in Cleveland, Ohio, with an ultimate completion date of September 30, 2026.

The effort builds on prior research into synthetic platelet nanotechnology designed to restore hemostasis, particularly for trauma patients and military combat-associated hemorrhage scenarios. The preclinical evaluation phase supports advancement of the Synthoplate technology toward field deployment capability.

Quick answers

Who was awarded contract HR0011259E017?

HR0011259E017 was awarded to Haima Therapeutics LLC by Defense Advanced Research Projects Agency (Department of Defense) on September 19, 2025.

How much is contract HR0011259E017 worth?

The government has obligated $2,000,000 on HR0011259E017.

Was contract HR0011259E017 competed?

The extent of competition for HR0011259E017 was competed.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award